WHO ICTRP trial
A Rollover Protocol to allow continued access to Tivozanib Hydrochloride…
NL-OMON39584 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON39584 |
|---|---|
| Public title | A Rollover Protocol to allow continued access to Tivozanib Hydrochloride (AV-951) for subjects enrolled in other Tivozanib Hydrochloride Protocols |
| Scientific title | A Rollover Protocol to allow continued access to Tivozanib Hydrochloride (AV-951) for subjects enrolled in other Tivozanib Hydrochloride Protocols - Continued Access to Tivozanib |
| Primary sponsor | AVEO pharamaceuticals |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Canada;India;Netherlands ;Russian Federation ;Ukraine;United States of America |
| Conditions | gastrointestinal cancer;10027656;gastrointestinal cancer |
| Interventions | Patients will receive tivozanib according to the previous guidelines of the study in which they participated. ;Rollover Protocol Continued Tivozanib |
| Registration date | Apr 14, 2014 |
| Target size | 10 |
| Secondary IDs | 2009-013407-66;NL30230.078.11 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: